EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

Claudio Jommi, Roberto Ravasio

AboutOpen · 21.11.2019 · 6 (1) · 78-85

DOI: 10.33393/abtpn.2019.302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AboutOpen, online erschienen am 21.11.2019. Verfasst von Claudio Jommi und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multicriteria Decision Analysis (MCDA) provides a framework that enhances transparency and repeatability of decisions taken on a multicriteria basis.

Objective

This analysis aims at assessing obinutuzumab compared to rituximab used as a first-line treatment for Follicular Lymphoma (FL) in the Italian health care system, using an MCDA approach. Materials and Methods: We used the EVIDEM V10 MCDA framework and a Delphi approach to scrutinize the views of a panel of physicians, payers and patients on value domains and their application to our research target.

Results

All stakeholders attached medium-high scores to FL severity (patients at higher risk of relapsing), unmet needs, obinutuzumab clinical benefit and evidence quality, and lower scores to organizational impact and, except for payers, to costs. The comparative analysis highlighted positive scores for the domains “incremental efficacy” (2.6: range −5/+5) and “incremental patient benefit” (1.5: range −5/+5) of obinutuzumab compared to rituximab. A slight increase of severe adverse events (≥3) for obinutuzumab was estimated by the panellists. Obinutuzumab compared to rituximab received a neutral evaluation for costs and for organizational impact.

Conclusion

This study reveals that MCDA could be a useful framework for evaluating a drug and it can be used to elicit the views of different stakeholder groups (as patients). The key criteria driving the value of obinutuzumab.

Zitieren

APA

Jommi, C., & Ravasio, R. (2019). The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA). AboutOpen, 6(1), 78-85. https://doi.org/10.33393/abtpn.2019.302

Vancouver

Jommi C, Ravasio R. The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA). AboutOpen. 2019;6(1):78-85. doi:10.33393/abtpn.2019.302

BibTeX
@article{Jommi2019,
  author = {Jommi, Claudio and Ravasio, Roberto},
  title = {The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)},
  journal = {AboutOpen},
  year = {2019},
  volume = {6},
  number = {1},
  pages = {78--85},
  doi = {10.33393/abtpn.2019.302}
}
Kostenlos starten →